Researchers looked at the outcomes of patients who experienced cutaneous toxic effects after treatment with anti–PD-1 therapy for advanced melanoma compared with patients who did not.
Researchers tested omitting chemotherapy from a treatment regimen involving dual blockade with pertuzumab and trastuzumab in patients with metastatic HER2+ breast cancer.
A phase III trial examined immunotherapy in patients with microsatellite-stable metastatic colorectal cancer.
Researchers will discuss new findings on continuous vs intermittent chemotherapy schedules in advanced breast cancer at the ESMO Breast Cancer Congress.
Researchers tested whether TP53 mutation status can determine the function of estrogen receptor-beta (ESR2) in patients with triple-negative breast cancer.
Researchers looked at the treatment failure rate for immunotherapy with R-CHOP in patients with diffuse large B-cell lymphoma who were occupationally exposed to pesticides.
A study of genetic testing in ovarian and breast cancer patients found substantial disparities in testing rates for ovarian cancer patients.
Researchers conducted the QUADRA trial to examine if niraparib could improve outcomes in heavily pretreated patients with ovarian cancer.
The number of patients reporting side effects related to chemotherapy increased by more than 40 percentage points after the implementation of a chemotherapy toxicity screening form.
The combination of trastuzumab and paclitaxel 'represents an important step forward in de-escalating therapy' for HER2+ breast cancer.